[ConservativeMind]

If you have cancer and your doctor has suggested a statin, maybe agreeing to take the lowest dose would be a good idea. The actual study showed no difference between the lowest and highest statin doses, for stopping cancer metastasis.

Atorvastatin (Lipitor) was best, followed in no particular order by fluvastatin (Lescol), pravastatin (Pravachol), and rosuvastatin (Crestor). Simvastatin (Zocor) had the lowest benefit.

[ConservativeMind]

The “Take Charge Of Your Health” Ping List

This potentially high volume ping list is for health articles and studies which describe something you or your doctor, when informed, may be able to implement for your benefit.

Now keeping a new list for conditions expected to concern at least 1% of the population. Ask to be on either the “Common Issues” or “Everything” list.

Please email or private message me if you want on or off of a list and of which list you desire.

[ConservativeMind]

From the study:

Notably, statin intake correlated with a significant reduction in cancer incidence (odds ratio [OR], .72; 95% confidence interval [CI], .70–.74). For statin-taking patients, we calculated a higher cancer survival probability versus subjects not taking any statins (Cox proportional-hazards model; hazards ratio [HR], .64; 95% CI, .48–.86). We found no difference for low-dose (20 mg: HR, 1.1; 95% CI, 0.89–1.37) versus high-dose (80 mg: HR, 1.11; 95% CI, .83–1.48) treatments; similarly, low-dose (10–20 mg: HR, .80; 95% CI, .59–1.09) and high-dose atorvastatin regimes (80 mg: HR, .72; 95% CI, .51–1.02) were comparable. When considering each statin separately, we found a strong cancer-preventive effect for atorvastatin (OR, .41; 95% CI, .38–.43) and significant effects for fluvastatin (OR, .7; 95% CI, .57–.85), pravastatin (OR, .63; 95% CI, .56–.71) and rosuvastatin (OR, .43; 95% CI, .36–.51); simvastatin showed only a weak cancer-preventive effect (OR, .9; 95% CI, .87–.94), and lovastatin effects were not readily assessed (relatively few patients; broad confidence intervals; Table S2).

We also considered the clinical data as a 1:1 matched-study design, using propensity score-matched sub-cohorts to better control for confounding associations that might stem from different distributions of age and gender between the whole dataset and the subset of cancer patients. We discovered further evidence supporting the cancer-preventive effect of statins (Figure 4 and Figure S4): (i) all statins considered together had an OR of .5 (95% CI, .48–.51), with (ii) atorvastatin .30 (95% CI, .28–.32), fluvastatin .65 (95% CI, .47–.88), lovastatin .51 (95% CI, .38–.7), pravastatin .47 (95% CI, .42–.54), rosuvastatin .32 (95% CI, .26–.38), and simvastatin .63 (95% CI, .61–.66).

[bitt]

p

[who_would_fardels_bear]

It's official: every drug cures every condition.

...except, of course, for the side-effects.

[Revel]

Statins do more harm than good.

[kalee]

For later

[logi_cal869]

Big mistake to be pursuing chemical modification of blood cholesterol on the basis of the fraudulent lipid hypothesis.

HUGE mistake, wrong direction.

[GOPJ]

Thanks for posting...